Takaharu Yamabe

Takaharu Yamabe

Pfizer Inc. - New York / United States
Others
AD Scientific Index ID: 4383152
-
person_outline Takaharu Yamabe's MOST POPULAR ARTICLES
1-) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trialG Agnelli, HR Buller, A Cohen, AS Gallus, TC Lee, R Pak, GE Raskob, ...Journal of Thrombosis and Haemostasis 13 (12), 2187-2191, 20152032015
2-) Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up periodF Berenbaum, FJ Blanco, A Guermazi, K Miki, T Yamabe, L Viktrup, ...Annals of the rheumatic diseases 79 (6), 800-810, 20201012020
3-) Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose …TI Nagashima, H., Suzuki, M., Araki, S., Yamabe, T., Muto, C.Osteoarthritis and Cartilage 19 (12), 1405-1412, 2011862011
4-) Micelle Formation and Surface Adsorption of N-(1,1-Dihydroperfluoroalkyl)-N,N,N-trimethylammonium ChlorideT Yamabe, Y Moroi, Y Abe, T TakahasiLangmuir 16 (25), 9754-9758, 2000392000
5-) Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trialG Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, R Pak, GE Raskob, ...Canadian Journal of Cardiology 30 (10), S278, 2014252014